These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 26818861)

  • 1. Serotonergic and Cholinergic Strategies as Potential Targets for the Treatment of Schizophrenia.
    Nikiforuk A
    Curr Pharm Des; 2016; 22(14):2093-116. PubMed ID: 26818861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. α7 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: Update on animal and clinical studies and strategies for the future.
    Terry AV; Callahan PM
    Neuropharmacology; 2020 Jun; 170():108053. PubMed ID: 32188568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3-Furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the α7 nicotinic receptor, reverses schizophrenia-like cognitive and social deficits in rats.
    Potasiewicz A; Hołuj M; Kos T; Popik P; Arias HR; Nikiforuk A
    Neuropharmacology; 2017 Feb; 113(Pt A):188-197. PubMed ID: 27717880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker.
    Hashimoto K
    Curr Pharm Des; 2015; 21(26):3797-806. PubMed ID: 26044974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α7 Nicotinic Acetylcholine Receptor: A Potential Target in Treating Cognitive Decline in Schizophrenia.
    Jones C
    J Clin Psychopharmacol; 2018 Jun; 38(3):247-249. PubMed ID: 29505470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors reverse ketamine-induced schizophrenia-like deficits in rats.
    Nikiforuk A; Kos T; Hołuj M; Potasiewicz A; Popik P
    Neuropharmacology; 2016 Feb; 101():389-400. PubMed ID: 26232639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel targets for drugs in schizophrenia.
    Stone JM; Pilowsky LS
    CNS Neurol Disord Drug Targets; 2007 Aug; 6(4):265-72. PubMed ID: 17691983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.
    Beinat C; Banister SD; Herrera M; Law V; Kassiou M
    CNS Drugs; 2015 Jul; 29(7):529-42. PubMed ID: 26242477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains.
    Citrome L
    J Clin Psychiatry; 2014; 75 Suppl 1():21-6. PubMed ID: 24581451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. α7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia.
    Freedman R
    Annu Rev Med; 2014; 65():245-61. PubMed ID: 24111888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α7 Nicotinic receptor-modulating agents reverse the hyperdopaminergic tone in the MAM model of schizophrenia.
    Neves GA; Grace AA
    Neuropsychopharmacology; 2018 Jul; 43(8):1712-1720. PubMed ID: 29695783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Cholinergic System: An Emerging Drug Target for Schizophrenia.
    Gibbons A; Dean B
    Curr Pharm Des; 2016; 22(14):2124-33. PubMed ID: 26818859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tropisetron enhances recognition memory in rats chronically treated with risperidone or quetiapine.
    Poddar I; Callahan PM; Hernandez CM; Yang X; Bartlett MG; Terry AV
    Biochem Pharmacol; 2018 May; 151():180-187. PubMed ID: 29175423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of 5-HT2A receptors in antipsychotic activity.
    Schmidt CJ; Sorensen SM; Kehne JH; Carr AA; Palfreyman MG
    Life Sci; 1995; 56(25):2209-22. PubMed ID: 7791509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The procognitive effects of 5-HT6 receptor ligands in animal models of schizophrenia.
    Nikiforuk A
    Rev Neurosci; 2014; 25(3):367-82. PubMed ID: 24501158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positive allosteric modulation of alpha 7 nicotinic acetylcholine receptors enhances recognition memory and cognitive flexibility in rats.
    Nikiforuk A; Kos T; Potasiewicz A; Popik P
    Eur Neuropsychopharmacol; 2015 Aug; 25(8):1300-13. PubMed ID: 26003081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and Development of Non-Dopaminergic Agents for the Treatment of Schizophrenia: Overview of the Preclinical and Early Clinical Studies.
    Jankowska A; Satała G; Partyka A; Wesołowska A; Bojarski AJ; Pawłowski M; Chłoń-Rzepa G
    Curr Med Chem; 2019; 26(25):4885-4913. PubMed ID: 31291870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential serotonergic agents for the treatment of schizophrenia.
    Garay RP; Bourin M; de Paillette E; Samalin L; Hameg A; Llorca PM
    Expert Opin Investig Drugs; 2016; 25(2):159-70. PubMed ID: 26576669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Schizophrenia drug discovery and development in an evolving era: are new drug targets fulfilling expectations?
    Dunlop J; Brandon NJ
    J Psychopharmacol; 2015 Feb; 29(2):230-8. PubMed ID: 25586401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the α7 nicotinic receptor in cognitive processing of persons with schizophrenia.
    AhnAllen CG
    Curr Opin Psychiatry; 2012 Mar; 25(2):103-8. PubMed ID: 22262029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.